Iambic Therapeutics, Inc. IAM

Iambic Therapeutics, Inc. integrates proprietary AI with automated chemistry and biology experimentation to discover and develop small-molecule drug candidates for cancer and other diseases. The company is based in San Diego, California, and sold 9,375,000 shares at $16.00 per share.

The net proceeds to the company are approximately $135.0 million for advancing clinical development of IAM1363, IAM217, and IAM-C1, and for continuing investment in its molecular superintelligence platform. The company holds all 9,375,000 shares offered.